Ceftin

Impetigo, Maxillary Sinusitis, Bacterial Meningitis + 17 more

Treatment

2 FDA approvals

20 Active Studies for Ceftin

What is Ceftin

Cefuroxime

The Generic name of this drug

Treatment Summary

Cephalosporin is an antibiotic used to fight a wide range of bacterial infections, including those caused by gram-positive and gram-negative bacteria, gonorrhea, and Haemophilus. It is resistant to beta-lactamase, which is an enzyme produced by bacteria that can make antibiotics less effective.

Zinacef

is the brand name

image of different drug pills on a surface

Ceftin Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Zinacef

Cefuroxime

1989

163

Approved as Treatment by the FDA

Cefuroxime, commonly known as Zinacef, is approved by the FDA for 2 uses such as Bacterial Infections and Urinary Tract Infection (UTI) .

Bacterial Infections

Urinary Tract Infection (UTI)

Effectiveness

How Ceftin Affects Patients

Cefuroxime is an antibiotic that interferes with the growth of certain bacteria. It works by blocking the formation of the walls that surround and protect the bacteria, which kills them. Cefuroxime is effective against bacteria like Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Neisseria gonorrhoeae, and Borrelia burgdorferi. Cefuroxime ax

How Ceftin works in the body

Cefuroxime works like penicillins. It attaches to proteins inside bacteria cells and stops the bacteria from making their cell walls. This leads to the breakdown of the cells, killing them. It may also prevent the bacteria from making an enzyme that stops cell breakdown.

When to interrupt dosage

The prescribed amount of Ceftin is contingent upon the identified ailment, including Gonorrhea, Urinary Tract Infection (UTI) and Bone and Joint Infections. The sum of dosage is determined by the methodology of delivery (e.g. Intravenous or Tablet, film coated) as specified in the table below.

Condition

Dosage

Administration

Maxillary Sinusitis

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

prophylaxis of infection in minor cuts, scrapes, or burns

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

Animal bite

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

Bacterial Infections

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

mild Streptococcal pharyngitis

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

moderate Streptococcal tonsillitis

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

Urinary Tract Infections

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

Osteomyelitis

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

Bronchitis, Chronic

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

Otitis Media

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

Tonsillitis

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

Septicemia

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

Urinary Tract Infection (UTI)

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

Impetigo

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

Bacterial Meningitis

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

moderate Streptococcal pharyngitis

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

Operative Surgery

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

Gonorrhea

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

Lyme Disease

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

Bronchitis

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

Warnings

Ceftin Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Ceftin.

Common Ceftin Drug Interactions

Drug Name

Risk Level

Description

Neomycin

Major

The risk or severity of nephrotoxicity can be increased when Cefuroxime is combined with Neomycin.

Tenofovir

Major

Cefuroxime may increase the nephrotoxic activities of Tenofovir.

Tenofovir alafenamide

Major

Cefuroxime may increase the nephrotoxic activities of Tenofovir alafenamide.

Tenofovir disoproxil

Major

Cefuroxime may increase the nephrotoxic activities of Tenofovir disoproxil.

Vibrio cholerae CVD 103-HgR strain live antigen

Major

The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Cefuroxime.

Ceftin Toxicity & Overdose Risk

An allergic reaction to cephalosporins may include rash, stuffy nose, coughing, sore throat, itchy eyes, or a severe life-threatening reaction known as anaphylaxis. Taking too much of this medication can also cause headaches and seizures.

image of a doctor in a lab doing drug, clinical research

Ceftin Novel Uses: Which Conditions Have a Clinical Trial Featuring Ceftin?

At present, 146 active trials are in progress to assess the potential of Ceftin in providing moderate Streptococcal pharyngitis relief, treating Bacterial Infections and Animal bite.

Condition

Clinical Trials

Trial Phases

Gonorrhea

0 Actively Recruiting

Operative Surgery

70 Actively Recruiting

Phase 3, Not Applicable, Phase 4, Phase 2, Early Phase 1

moderate Streptococcal pharyngitis

0 Actively Recruiting

prophylaxis of infection in minor cuts, scrapes, or burns

0 Actively Recruiting

Maxillary Sinusitis

0 Actively Recruiting

Septicemia

1 Actively Recruiting

Not Applicable

Tonsillitis

0 Actively Recruiting

Bronchitis, Chronic

0 Actively Recruiting

moderate Streptococcal tonsillitis

0 Actively Recruiting

Bronchitis

2 Actively Recruiting

Not Applicable

Lyme Disease

2 Actively Recruiting

Phase 1, Phase 2, Not Applicable

Bacterial Meningitis

0 Actively Recruiting

Animal bite

0 Actively Recruiting

Otitis Media

0 Actively Recruiting

Impetigo

0 Actively Recruiting

Bacterial Infections

0 Actively Recruiting

mild Streptococcal pharyngitis

0 Actively Recruiting

Urinary Tract Infections

9 Actively Recruiting

Not Applicable, Phase 4, Early Phase 1

Osteomyelitis

0 Actively Recruiting

Urinary Tract Infection (UTI)

6 Actively Recruiting

Phase 1, Phase 3, Phase 4, Phase 2

Ceftin Reviews: What are patients saying about Ceftin?

5

Patient Review

12/22/2013

Ceftin for Bacterial Urinary Tract Infection

Ceftin is the only antibiotic that doesn't make my chronic constipation worse, and I really appreciate that. It's also helped me avoid other problems, like yeast infections, that come with taking other antibiotics.

5

Patient Review

12/31/2015

Ceftin for Acute Maxillary Sinus H. Influenzae Bacteria Infection

I took 500mg twice daily for 10 days as directed. I felt great at day 7 and had no issues with the medication - results were great!

5

Patient Review

12/3/2018

Ceftin for Lyme Disease

I've been on this medication for almost a month now, and was initially worried about side effects. The worst one I've experienced is constipation, but it seems to be helping with my Lyme disease symptoms. I take 500mg twice a day, and have had no problems tolerating it on an empty stomach.

4.7

Patient Review

6/25/2013

Ceftin for Bacterial Urinary Tract Infection

I generally have a lot of anxiety and negative side effects when taking antibiotics, but this medication was different. It didn't make me feel as bad. The taste is really gross when swallowing it, but i had no other side effects. I was prescribed to take 2 pills a day for 3 days and i felt better by the second day but i finished all 6 pills.

4.7

Patient Review

3/28/2015

Ceftin for Strep Throat and Tonsillitis

Despite the terrible taste, I'm really glad I took this medication. I woke up feeling great after the first dose, and my back pain (which has been constant since spinal surgery four months ago) completely disappeared. I highly recommend it to anyone in a similar situation!

4.7

Patient Review

5/27/2017

Ceftin for Urinary Tract Infection due to E. Coli Bacteria

There aren't many options available to me as I'm allergic to Macrobid and Bactrim, but Cipro really did the trick in getting rid of my infection. The generic form doesn't have a terrible taste, which is great. As with any antibiotic, make sure you take it with food and drink lots of water while you're taking the medication.

4.3

Patient Review

6/5/2015

Ceftin for Pneumonia caused by Bacteria

I think this medicine is helping with my bronchitis, though I can't be sure. What I do know is that it's giving me serious insomnia, which is something I've never struggled with before.

4

Patient Review

5/27/2015

Ceftin for Middle Ear Infection

I was prescribed 500mg Ceftin 2x/day for 10 days for an ear infection. I lost all sense of taste and smell for the entire ten days except for a stong chemical taste on my tongue. My last dose was 15 hours ago and I have just gotten back a small sense of smell. I was also extremely fatigued the entire time.

4

Patient Review

5/26/2017

Ceftin for Urinary Tract Infection due to E. Coli Bacteria

I found that I can take this one, even though I'm allergic to most of the main antibiotics used for urinary tract infections. The generic does not have the horrible taste, but you must take it with food and drink plenty of water. I hate taking it because it makes me feel awful at first, but then after a few days, I get used to it. It does help my urinary tract infections.

3.7

Patient Review

5/31/2013

Ceftin for Bacterial Urinary Tract Infection

I had a UTI and it was awful. The taste is really bad, and it's expensive without insurance. I was scared to take it at first because of the side effects, but none of them happened. However, I did have bad stomach pain afterwards so I took it with water and yogurt to help with the pain and taste. Overall, it helped me get rid of my UTI.

2.3

Patient Review

3/6/2014

Ceftin for Acute Maxillary Sinus H. Influenzae Bacteria Infection

This medication was ineffective in treating my sinus infection, as well as those of friends and family members. I am concerned that this drug is being marketed as effective when it so clearly is not.

2.3

Patient Review

6/13/2013

Ceftin for Bacterial Pneumonia caused by Streptococcus

Not only was this medicine ineffective, but it actually made my blood sugar level rise and gave me mouth thrush.

2.3

Patient Review

3/15/2015

Ceftin for Bacterial Infection with Chronic Bronchitis

I was prescribed this medication for a cough and cold. However, I ended up with a terrible case of 'C diff' colitis. Now, I'm on Flagyl to clear the infection up. I hope I never have to take another antibiotic again!

1.7

Patient Review

5/9/2013

Ceftin for Middle Ear Infection

I'm still experiencing symptoms even after a week of treatment.

1.7

Patient Review

4/8/2021

Ceftin for Pneumonia caused by Bacteria

I took this for pneumonia and it only made things worse. I felt extremely confused, nauseous, and had a terrible headache on top of the other effects listed in the title.

1.7

Patient Review

7/16/2014

Ceftin for Strep Throat

I was diagnosed with strep throat and prescribed this medication. I experienced no relief after the recommended five days, and the taste is incredibly unpleasant. Overall, a very negative experience.

1

Patient Review

4/30/2014

Ceftin for Urinary Tract Infection caused by Klebsiella Bacteria

Blurry vision, burning while urinating, nausea, and upset stomach are just some of the issues I had while taking this medication. My doctor prescribed it for a month, 500mg twice daily.

1

Patient Review

12/14/2013

Ceftin for Acute Inflammation of the Maxillary Sinus

Unfortunately, this medication made me feel worse rather than better. The side effects were really unpleasant and not worth it.

1

Patient Review

8/8/2016

Ceftin for Urinary Tract Infection due to E. Coli Bacteria

I had a urine test done by a lab tech, who found bacteria in the urine - E.coli. I took 2 pills a day for 5 days, at which time I stopped because I had vaginal bleeding. Since then, I have been having severe urinary tract infection.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about ceftin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the drug Ceftin used to treat?

"It will not work for viral infections (such as common cold, flu).

Cefuroxime is used to treat a variety of bacterial infections. This medication is a cephalosporin antibiotic and works by stopping the growth of bacteria. This antibiotic only treats bacterial infections and will not work for viral infections."

Answered by AI

Is Ceftin and Cipro the same?

"The study found that ciprofloxacin and cefuroxime axetil were both effective in treating community-acquired acute sinusitis, with similar rates of bacteriologic eradication at the end of therapy. Both treatments were well tolerated."

Answered by AI

Is Ceftin in the penicillin family?

"Amoxicillin and Ceftin are two different types of antibiotics. Amoxicillin is a penicillin-type antibiotic, while Ceftin is a cephalosporin antibiotic. Both medications can cause side effects like diarrhea, abdominal pain, nausea, vomiting, and rash. Allergic reactions are also possible with both amoxicillin and Ceftin."

Answered by AI

Is cefuroxime stronger than amoxicillin?

"Our results showed that cefuroxime axetil given twice a day was just as effective in treating acute bacterial maxillary sinusitis as amoxicillin/clavulanate given three times a day, but cefuroxime axetil caused fewer side effects."

Answered by AI

Clinical Trials for Ceftin

Image of Children's of Alabama in Birmingham, United States.

Antibiotic Duration for Infections in Children

60 - 17
All Sexes
Birmingham, AL

Infections like pneumonia, skin and soft tissue infection (also called SSTI or cellulitis), and urinary tract infections (UTI) are some of the most common reasons children get admitted to the hospital. All three of these conditions require antibiotics for treatment. Although antibiotics are needed to treat the infection and help children feel better, taking them longer than needed can negatively impact children and their families. Negative impacts include things like the burdens of taking more medications and medication side effects. There are guidelines (instructions) from expert medical organizations that suggest the number of days children need antibiotics, but they give a wide range (between 5 and 14 days). Unfortunately, these guidelines are not based on high-quality studies. National data suggests that doctors often choose on the higher end of this range when writing prescriptions for children in the hospital. Our three caregiver co-investigators, other parents of hospitalized children, doctors, other care providers, and researchers, all believe that additional study is needed to determine the best length of antibiotic treatment that weighs both the benefits and harms of antibiotics. The goal of our study is to understand if 5 total days of antibiotic treatment compared to 10 total days of antibiotic treatment is better for children who have been in the hospital for pneumonia, SSTI, or UTI. We will study this question through a randomized control trial. In other words, half of the children will receive 5-days of antibiotics and the other half will receive 10-days of antibiotics. Children in this study (and their caregivers) will not know how many days of antibiotics they will receive to cure their infection because some children will take a placebo (or a pill without antibiotics in it). Only the pharmacy will know if a child is getting antibiotic or placebo (for days 6-10 of treatment). During the first phase of the trial (feasibility phase), 4 hospitals will enroll children in the study. We plan on enrolling 50 patients during this phase. We are starting with just 4 hospitals, so our study team can create and update our study plans if needed. We will closely review information about how many patients and families agree to participate, and if they have any trouble completing any part of the study. We will also interview families to understand the choice to participate in the study, the choice not to participate in the study, and what it is like to be in the study. During the second study phase, we will enroll 1150 more patients across all 11 hospitals. Families will complete short, daily surveys until the 15th day after they started antibiotics, then a larger survey at day 15, at day 20, and at day 30. These surveys will ask about the child's symptoms and recovery from their illness, how the antibiotics are making them feel, and if they had to go back to their doctor, emergency room, or hospital. The answers to these questions will be combined to measure how well the child did, balancing feeling better and having bad effects from the antibiotics. We will use mathematical tests to determine which antibiotic duration is better for treating these illnesses. We will complete other mathematical tests to see if all children should receive the same length of antibiotics or if certain children should be prescribed shorter courses and others longer courses.

Phase 4
Waitlist Available

Children's of Alabama (+9 Sites)

Sunitha V Kaiser, MD, MSc

Image of Medstar National Rehabilitation Hospital in Washington D.C., United States.

Lactobacillus Crispatus for Urinary Tract Infection

18+
All Sexes
Washington D.C., United States

The goal of this clinical trial is to determine whether Lactobacillus crispatus strains isolated from the lower urinary tracts of adult women can be used as an antibiotic-sparing treatment for urinary symptoms and urinary tract infection (UTI) among adults with neurogenic lower urinary tract dysfunction (NLUTD). The main question\[s\] it aims to answer are: 1. To identify soluble bactericidal compounds produced by urinary isolates of L. crispatus that kill uropathogenic E. coli (UPEC). 2. To determine if intravesical instillation of L. crispatus is safe and well tolerated in adults with NLUTD due to SCI who use intermittent catheterization (IC). If there is a comparison group: Researchers will compare L. Crispatus to standard care saline to see if there is a difference in urinary symptoms and urinary microbiome. Participants will be asked to complete daily symptom surveys, complete 2 bladder instillations, and collect, freeze, and return 14 urine samples.

Phase < 1
Recruiting

Medstar National Rehabilitation Hospital

Suzanne Groah, MD

Image of Baylor College of Medicine in Houston, United States.

Educational Tool for Urinary Tract Infections

18+
All Sexes
Houston, TX

Urine culture is the most common microbiological test in the outpatient setting in the United States. Unfortunately, contamination during collection is prevalent and undermines test accuracy, leading to incorrect diagnosis, unnecessary treatment, wasted laboratory resources, and inflated costs. Unnecessary antibiotic treatment increases the risk of developing antimicrobial resistance, one of the most serious threats to patients and public health. The goal of this clinical trial is to test whether a bilingual (English and Spanish) educational intervention, an animated video and pictorial flyer, can reduce urine culture contamination and associated inappropriate antibiotic use in adult patients visiting safety-net primary care clinics. The main questions it aims to answer are: 1. Does providing patients with a bilingual educational intervention reduce urine culture contamination rates? 2. Does the intervention lead to fewer unnecessary urinary antibiotic prescriptions? 3. Does providing patients with a bilingual educational intervention reduce contaminated urinalyses? Researchers will compare patients randomized to receive the educational intervention (video and flyer) to those receiving usual care to see if the intervention improves urine collection accuracy and reduces inappropriate antibiotic use. Participants will watch a short, animated video with step-by-step instructions for proper midstream clean-catch urine (MSCC) collection, receive a pictorial flyer (with stills from the video) reinforcing the instructions, and provide a urine sample for culture. Hypothesis: patients who receive the educational intervention will have: lower urine culture contamination rates (primary outcome), fewer urinary antibiotic prescriptions (secondary outcome), and fewer contaminated urinalyses (secondary outcome). The objectives are to (1) develop educational tools: Create an animated video and pictorial flyer with step-by-step urine collection instructions for women and men, developed through an iterative, stakeholder-engaged process, (2) assess acceptability: Use mixed methods (quantitative surveys and qualitative interviews) to evaluate and refine the tools for usability and cultural/linguistic appropriateness, and (3) test effectiveness: Conduct a randomized controlled trial to assess the intervention's impact on urine contamination rates, antibiotic prescribing, and patient satisfaction.

Waitlist Available
Has No Placebo

Baylor College of Medicine

Larissa Grigoryan, MD, PhD

Have you considered Ceftin clinical trials?

We made a collection of clinical trials featuring Ceftin, we think they might fit your search criteria.
Go to Trials
Image of UPMC Shadyside Hospital in Pittsburgh, United States.

Bright Green Light Therapy for Postoperative Pain

18+
All Sexes
Pittsburgh, PA

This is an unblinded, parallel group randomized controlled trial to evaluate bright green light as an adjunct therapy after surgery at UPMC Shadyside. The primary outcome measure will be pain intensity with secondary outcome measures including opioid requirements, sleep quality, mood, and overall post-operative recovery. Specific aims/hypotheses for this study are as follows: Aim 1: To assess bright green light therapy's potential as a complementary post-operative analgesic strategy in patients recovering from surgery Hypothesis 1: Participants exposed to bright green light, in comparison to dim white (ambient) light, will have improved postoperative pain scores and lower opioid use. Aim 2: To examine the impact of bright green light therapy on patient-centered measures of post-operative recovery that may be related to improved circadian function. Hypothesis 2: Participants exposed to bright green light, in comparison to dim white (ambient) light, will have improved quality of post-operative recovery, enhanced sleep, and reduced anxiety and depression.

Waitlist Available
Has No Placebo

UPMC Shadyside Hospital

Rebecca Kotcher, MD

Image of Walter Reed National Military Medical Center in Bethesda, United States.

Corticosteroid Injections for Osteoarthritis

18+
All Sexes
Bethesda, MD

The goal of this clinical trial is to find out which type of steroid medicine, when added to a standard pain-control injection during total knee replacement surgery, works best at reducing pain, limiting opioid use, and improving recovery in adults undergoing surgery for severe knee arthritis or injury. The main questions it aims to answer are: Does adding a steroid to the injection improve pain control and reduce opioid use after surgery? Is the newer extended-release steroid (Zilretta) more effective and safer-especially for patients with diabetes-than the traditional steroid (methylprednisolone)? Researchers will compare: Standard pain-control injection alone Standard injection plus methylprednisolone Standard injection plus Zilretta to see which option provides better pain relief, less opioid use, and improved knee function. (Patients with diabetes or prediabetes will only be in the standard injection or Zilretta groups so researchers can study whether Zilretta is safer for blood sugar control.) Participants will: Be randomly assigned to one of the study groups during their total knee replacement surgery Receive the assigned pain-control injection around the knee joint Be followed after surgery to measure: Pain levels Opioid pain medication use Knee movement (range of motion) Whether another procedure (such as manipulation under anesthesia) is needed if the knee becomes too stiff Patient-reported outcome surveys about pain and function

Phase 2 & 3
Waitlist Available

Walter Reed National Military Medical Center

John P Cody, MD

Have you considered Ceftin clinical trials?

We made a collection of clinical trials featuring Ceftin, we think they might fit your search criteria.
Go to Trials
Image of UPMC Magee-Womens Hospital in Pittsburgh, United States.

Catheterization Methods for Postpartum Urinary Problems

18+
All Sexes
Pittsburgh, PA

At least ten percent of patients have postpartum urinary retention or difficulty urinating after birth, which can cause incontinence and other urinary problems long-term. After getting an epidural placed, patients should be numb in their pelvic region. This numbness makes it difficult to feel the need to urinate, so patients need a urinary catheter placed to empty the bladder. Some patients have one catheter placed throughout their labor and others have a catheter placed to empty the bladder then removed every few hours. The investigators are studying whether placing a catheter once or catheterizing multiple times affects the rate of postpartum urinary problems and infection.

Waitlist Available
Has No Placebo

UPMC Magee-Womens Hospital

Anna Binstock, MD

Image of University of California, San Francisco in San Francisco, United States.

Trimethoprim-Sulfamethoxazole for Urinary Tract Infections

13 - 29
All Sexes
San Francisco, CA

The goal of this clinical trial is to learn if a common antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX) can help prevent urinary tract infections (UTIs) in children and young adults who recently had a kidney transplant. Most people take TMP-SMX for about 6 months after getting a kidney transplant. In this study, researchers want to see what happens if people keep taking it for 6 more months. The main questions this study is asking are: * Does TMP-SMX lower the number of UTIs in the first year after transplant? * What side effects or problems do participants have while taking TMP-SMX? Researchers will compare TMP-SMX to a placebo (a look-alike pill that does not contain any medication) to see if TMP-SMX works to prevent UTIs. Participants will: * Take either TMP-SMX or a placebo pill by mouth every day for 6 months * Have three visits to touch base with the study team about any issues * Complete short monthly online surveys about any symptoms or side effects * Share blood and urine test results from their regular transplant clinic visits

Phase 4
Waitlist Available

University of California, San Francisco

Alexandra Bicki, MD

Have you considered Ceftin clinical trials?

We made a collection of clinical trials featuring Ceftin, we think they might fit your search criteria.
Go to Trials